Publications by authors named "M Redman"
Introduction: Thymic carcinoma is a rare and aggressive malignancy with few treatment options. Preclinical studies suggested that targeting the angiogenic pathway may be beneficial in this disease.
Methods: This randomized phase 2 trial enrolled patients with unresectable, locally advanced, recurrent, or metastatic thymic carcinoma.
Article Synopsis
- The study aimed to assess if adding the PARP inhibitor talazoparib to the immune checkpoint inhibitor atezolizumab could enhance outcomes for patients with SLFN11-positive extensive stage small cell lung cancer (ES-SCLC) after initial treatment.
- A total of 106 patients were randomized into two groups, showing that the combination therapy (talazoparib plus atezolizumab) led to improved progression-free survival compared to atezolizumab alone, though overall survival rates remained similar between the two groups.
- While the combination therapy improved progression-free survival, it also resulted in higher rates of severe hematological side effects, such as grade 3 anemia, highlighting the need for careful patient selection based on genetic markers
Purpose: Targeted therapy development in soft tissue sarcoma (STS) has been burdened by the heterogeneity of this group of rare tumors. B7 homolog 3 protein (B7-H3) is a molecule in the same family as programmed death-ligand 1 (PD-L1). It has limited expression in noncancerous tissues and is overexpressed in many cancers, making it an attractive target for cancer therapy, and clinical trials targeting B7-H3 are actively underway.
View Article and Find Full Text PDFIntroduction: Squamous cell cancer (SqCC) is a lung cancer subtype with few targeted therapy options. Molecular characterization, that is, by next-generation sequencing (NGS), is needed to identify potential targets. Lung Cancer Master Protocol Southwest Oncology Group S1400 enrolled patients with previously treated stage IV or recurrent SqCC to assess NGS biomarkers for therapeutic sub-studies.
View Article and Find Full Text PDFClinical trials are essential for advancing oncology treatment strategies and have contributed significantly to the decline in cancer mortality rates over the past decades. Traditional explanatory trials, focused on establishing intervention efficacy in ideal settings, often lack generalizability and may not reflect real-world patient care scenarios. Furthermore, increasing complexity in cancer clinical trial design has led to challenges such as protocol deviations, slow enrollment leading to lengthened durations of trial, and escalating costs.
View Article and Find Full Text PDF